Motilin

What is Motilin?

Motilin is a 22-amino-acid linear peptide hormone produced by enteroendocrine M cells (sometimes called Mo cells) scattered through the duodenal and proximal jejunal mucosa, with smaller populations in the stomach and pancreas. It was discovered serendipitously by John Christopher Brown and colleagues at the University of British Columbia in Vancouver: while studying secretin-stimulated pancreatic secretion in dogs in the mid-1960s, Brown noticed that crude duodenal extracts unexpectedly stimulated gastric motor activity rather than inhibiting it, and the active principle was named 'motilin' for that motility-stimulating property. The team purified the peptide from porcine intestinal mucosa over the next several years (Can J Physiol Pharmacol 1971, Gastroenterology 1972) and reported the complete 22-residue amino acid sequence in 1973 (Can J Biochem). Motilin signals through a single G-protein-coupled receptor of the rhodopsin family — the motilin receptor MLNR (also known as GPR38 or MTLR1) — cloned in 1999 by Susan Feighner and colleagues at Merck (Science). The receptor is most heavily expressed on enteric cholinergic neurons innervating gastric smooth muscle, with secondary expression in the pituitary and other tissues. Plasma motilin oscillates cyclically during fasting in close synchrony with the gastric phase III of the migrating motor complex (MMC) — the so-called 'housekeeping wave' of high-amplitude propulsive contractions that sweeps undigested debris and bacteria from stomach to colon roughly every 90-120 minutes. The discovery in 1989 (Peeters and colleagues) that the macrolide antibiotic erythromycin is a potent non-peptide motilin receptor agonist transformed motilin from a basic-physiology curiosity into a translational drug target, and motilin receptor agonist prokinetics — erythromycin, mitemcinal, atilmotin, camicinal, and other 'motilides' — have been pursued for decades as treatments for gastroparesis, post-operative ileus, and feed intolerance in critical illness, with a long string of late-phase clinical disappointments.

What Motilin Is Investigated For

Motilin is an endogenous-physiology and drug-target topic, not a peptide consumers take. Its clinical relevance runs through two channels. First, motilin and its M-cell biology are the textbook explanation for the migrating motor complex — the cyclic fasting motor pattern that empties the stomach and small intestine of debris between meals. Loss of MMC activity is implicated in gastroparesis, small intestinal bacterial overgrowth, and post-operative ileus, which is why motilin biology matters clinically even though motilin itself is not given as a drug. Second, the motilin receptor (MLNR/GPR38) is one of the most-pursued GPCR drug targets in gastroenterology. Erythromycin's accidental prokinetic effect — first identified as a motilin agonist by Theo Peeters and colleagues in Leuven in 1989 — established the proof of concept, and macrolide-derived 'motilides' (mitemcinal/GM-611, ABT-229, atilmotin) and structurally distinct selective agonists (camicinal/GSK962040 from GSK, KC 11458) have been advanced into late-phase trials for diabetic gastroparesis and ICU feed intolerance. The clinical record has been disappointing: ABT-229 failed in randomised diabetic gastroparesis trials, mitemcinal showed efficacy only in select subgroups, and camicinal produced acute prokinetic effects in critically ill patients but did not deliver durable symptomatic benefit. The honest framing is that motilin is foundational physiology with a clear, single-receptor mechanism, but tachyphylaxis (rapid tolerance with chronic dosing), narrow therapeutic windows, and heterogeneous gastroparesis populations have repeatedly defeated drug development. The field remains active, with renewed interest driven by the cryo-EM structure of the motilin receptor and bias-aware ligand design (Sanger and colleagues).

History & Discovery

Motilin's discovery is one of the cleanest serendipity stories in gut endocrinology. In the mid-1960s, John Christopher Brown — a young investigator at the University of British Columbia in Vancouver, working with Viktor Mutt's purification methods from the Karolinska Institute — was studying the effects of crude duodenal mucosal extracts on pancreatic secretion in dogs, looking for new secretin-like activities. He noticed that some extract fractions, instead of inhibiting gastric motor activity (as secretin did), strongly stimulated it. Brown named the responsible factor 'motilin' for that motility-stimulating property. Over the next several years his group at UBC purified the peptide from porcine duodenal mucosa: the 1971 Canadian Journal of Physiology and Pharmacology paper (Brown, Mutt, and Dryburgh) reported further purification of the gastric-motor-activity-stimulating polypeptide; the 1972 Gastroenterology paper provided final purification, amino acid composition, and C-terminal characterization; and the 1973 Canadian Journal of Biochemistry paper (Brown, Cook, and Dryburgh) reported the complete 22-residue amino acid sequence — a structural reference for the field. Motilin became the second canonical small-intestinal hormone of the modern era after secretin, and Brown's Vancouver group is permanently associated with its discovery alongside their better-known characterization of GIP (gastric inhibitory polypeptide). The physiological role of motilin came into focus through the work of Z. Itoh and colleagues in Japan in the 1970s, who established the link between cyclic plasma motilin elevations and the gastric phase III of the migrating motor complex in dogs. The MMC itself — the three-phase fasting motor cycle of the upper gut — had been described by Joel Szurszewski in 1969, and the recognition that motilin was its principal hormonal driver gave the system a clear mechanistic frame. Theo Peeters and colleagues at the University of Leuven extended this work into human physiology over the 1980s and 1990s, characterizing plasma motilin dynamics, the MMC, and the effects of exogenous motilin and motilin receptor agonists. The transformative pharmacological discovery came in 1989: Peeters, Matthijs, and Depoortere reported in the American Journal of Physiology that the 14-membered macrolide antibiotic erythromycin is a direct agonist at the motilin receptor, reproducing motilin's prokinetic effects at concentrations well below its antibiotic activity. The 1990 New England Journal of Medicine paper from Janssens, Peeters, and Vantrappen translated this into clinical use, showing that erythromycin accelerates gastric emptying in diabetic gastroparesis. Erythromycin remains the most widely used motilin receptor agonist in clinical practice, prescribed off-label for gastroparesis and post-operative ileus despite recognized limitations of tachyphylaxis, QT prolongation, and antibiotic stewardship concerns. The motilin receptor itself was molecularly characterized in 1999: Susan Feighner and colleagues at Merck Research Laboratories cloned the human motilin receptor (MLNR/GPR38) and reported it in Science, establishing it as a single rhodopsin-family GPCR closely related to the ghrelin receptor. This launched the modern era of selective motilin receptor agonist drug development. The clinical record has been disappointing: ABT-229 (alemcinal, Abbott) failed in a randomised diabetic gastroparesis trial reported by Nicholas Talley and colleagues in Gut 2001; mitemcinal (GM-611, Chugai) showed only subgroup-specific efficacy, summarized by Takanashi and Cynshi in their 2009 Regulatory Peptides review titled 'Motilides: a long and winding road'; atilmotin reached early-phase trials and was discontinued; and camicinal (GSK962040, GlaxoSmithKline) — a structurally distinct selective motilin agonist — produced acute prokinetic effects in critically ill feed-intolerant patients (Chapman, Deane, and colleagues, Crit Care 2016) and in type 1 diabetes with gastroparesis (Hellstrom, Tack, and colleagues, Br J Pharmacol 2016) but did not progress to approval. Renewed interest in the field has been driven by structural biology of the motilin receptor and biased-agonist design strategies (Sanger, Broad, Callaghan, and Furness 2017), as well as the recognition that motilin contractions transmit hunger signals to the brain (Tack, Deloose, and Ang, Gut 2016) — adding a feeding-behavior dimension to a hormone previously understood almost entirely as a motor regulator.

How It Works

Motilin is a hormone your gut releases on a roughly 90-minute timer when you haven't eaten in a while. When it gets released, it tells your stomach to start contracting forcefully — a kind of self-cleaning wave that pushes leftover food and bacteria from your stomach down through your small intestine. Eating shuts the cycle off; fasting starts it back up. Doctors discovered by accident that the antibiotic erythromycin happens to bind the same receptor that motilin uses, which is why erythromycin is sometimes prescribed in low doses to help patients whose stomachs do not empty properly (a condition called gastroparesis). Drug companies have tried for decades to make better, cleaner versions of erythromycin specifically for stomach motility, but most have failed in late-stage trials.

Motilin is a 22-amino-acid linear peptide (FVPIFTYGELQRMQEKERNKGQ in human, with a single conserved sequence across most mammals) cleaved from a 119-residue prepromotilin precursor encoded by the MLN gene on human chromosome 6p21.31. It is produced almost exclusively by enteroendocrine M cells (Mo cells) of the duodenal and proximal jejunal mucosa, with the highest density in the duodenum and a sharp gradient of decreasing density distally. Motilin signals through a single G-protein-coupled receptor of the rhodopsin family — the motilin receptor MLNR (also GPR38, MTLR1) — cloned in 1999 by Feighner and colleagues at Merck Research Laboratories and reported in Science. The motilin receptor is closely related (~52% sequence identity) to the ghrelin receptor GHSR, and the two are the only members of a small subfamily — a phylogenetic relationship that has motivated combined motilin/ghrelin pharmacology programs (Sanger and Furness, Nat Rev Gastroenterol Hepatol 2016). Receptor coupling is predominantly Gq/11, mobilizing intracellular calcium through phospholipase-C-mediated IP3 generation, with secondary coupling to Gi/o pathways depending on cellular context. The dominant anatomical site of action in the upper gut is the cholinergic enteric neuron innervating gastric smooth muscle: motilin receptor activation on these neurons triggers acetylcholine release, which in turn drives high-amplitude muscarinic contractions of the antrum and proximal duodenum. Direct effects on smooth muscle exist but are smaller in magnitude than the neural pathway. The motilin receptor is also expressed in the pituitary (where it modulates GH and prolactin secretion under some conditions), the colon (with a less prominent prokinetic role), and elsewhere — but the clinically dominant effect is gastric. The central physiological role of motilin is generation of the gastric phase III of the migrating motor complex (MMC), the cyclic 'housekeeping wave' of high-amplitude propulsive contractions that occurs roughly every 90-120 minutes during fasting. Plasma motilin oscillates in tight synchrony with each gastric phase III: motilin rises sharply just before phase III onset, peaks at the height of contractile activity, and falls back to baseline as phase III migrates distally and the system enters phase I quiescence. The 2015 Deloose paper in Neurogastroenterology and Motility provided the cleanest demonstration of this synchrony in humans, showing that motilin (but not ghrelin) plasma levels track gastric phase III activity. Eating immediately interrupts the MMC and switches the system into the postprandial pattern; the trigger that resumes MMC cycling several hours later is incompletely understood but involves vagal input, falling postprandial nutrient signals, and intrinsic enteric pacemaker activity. A notable property of macrolide antibiotics — first established by Peeters, Matthijs, and Depoortere in 1989 — is that 14-membered ring macrolides such as erythromycin act as direct agonists at the motilin receptor at concentrations well below their antibiotic minimum inhibitory concentrations. This 'motilide' activity has been engineered out (or in) in dozens of macrolide derivatives, producing a class of motilin agonist prokinetic candidates. Tachyphylaxis — rapid receptor desensitization with chronic dosing — is the principal pharmacological obstacle: chronic motilin receptor agonism rapidly downregulates surface receptor expression, eroding clinical efficacy within days to weeks. Motilin biology also intersects with hunger perception: gastric phase III contractions driven by motilin transmit a signal interpreted centrally as hunger (Tack and colleagues, Gut 2016), with erythromycin able to acutely stimulate hunger and food intake in healthy humans through a cholinergic pathway (Deloose and colleagues, Am J Clin Nutr 2016).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Motilin:

• 01Whether biased motilin receptor agonists — designed to selectively engage signaling pathways that drive prokinetic activity without recruiting the desensitization machinery — can deliver durable clinical benefit in gastroparesis without the tachyphylaxis that has defeated every prior agonist.
• 02Whether motilin/ghrelin dual agonists or selective combinations — exploiting the close phylogenetic and structural relationship between MLNR and GHSR — can outperform single-receptor strategies in gastroparesis or post-operative ileus.
• 03The contribution of impaired motilin/MMC activity to small intestinal bacterial overgrowth (SIBO), and whether motilin agonist therapy could be a targeted strategy for SIBO in patients with documented MMC deficiency.
• 04Whether motilin-driven hunger signaling represents a viable target for appetite modulation in clinical conditions — particularly cachexia, anorexia, and post-bariatric weight regain — given the demonstrated ability of motilin contractions to transmit hunger signals centrally (Tack 2016).
• 05The mechanism that resumes the migrating motor complex several hours after a meal, and how this is integrated with motilin release from M cells — a question with clinical relevance for gastroparesis and post-operative ileus.
• 06Whether selective motilin receptor agonists have a meaningful role in functional dyspepsia and idiopathic gastroparesis, populations where the clinical heterogeneity has confounded all prior late-phase trials.
• 07The pharmacological and clinical consequences of recently-published cryo-EM structures of the motilin receptor for next-generation drug design, including allosteric ligands and structurally novel chemotypes that avoid macrolide-class liabilities.

Forms & Administration

Motilin is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic porcine or human motilin (1-22) for in vitro motilin receptor binding and signaling assays, isolated tissue pharmacology, and intravenous infusion studies in animals and a small number of human research protocols (typically 0.05-0.4 nmol/kg/min infusions). The clinically relevant molecules are motilin receptor agonists — erythromycin (used off-label intravenously or orally as a prokinetic for gastroparesis at sub-antibiotic doses) and investigational small-molecule agonists (camicinal, mitemcinal historically) — rather than motilin itself. Compounded motilin from peptide marketplaces has no validated clinical use.

Common Questions

Who Motilin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for motilin itself because no motilin product has been clinically developed. The clinically relevant interactions concern motilin receptor agonist drugs, particularly erythromycin: erythromycin is a potent CYP3A4 inhibitor with extensive interactions (statins, calcium channel blockers, warfarin, benzodiazepines, immunosuppressants), prolongs the QT interval (with risk of torsades de pointes when combined with other QT-prolonging drugs such as fluoroquinolones, antipsychotics, methadone, ondansetron), and exhibits well-known antibiotic-related interactions including disruption of the gut microbiome. Selective non-macrolide motilin agonists (camicinal) avoid the CYP3A4 inhibition but still drive strong gastric contractions that could theoretically interact with mechanical-obstruction-relevant medications, anticoagulants in the setting of GI hemorrhage risk, and other prokinetics (metoclopramide, prucalopride, domperidone) by additive motor effects. Tachyphylaxis at the motilin receptor is itself a pharmacological obstacle that has limited the duration of clinical benefit for every motilin agonist tested in chronic dosing regimens. None of these interactions has been characterized for exogenous motilin in controlled human studies; they are mechanistic and class-extrapolated possibilities that argue against casual exogenous motilin or motilin agonist exposure outside clinical care.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions